1. Home
  2. ABCL vs COLL Comparison

ABCL vs COLL Comparison

Compare ABCL & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABCL
  • COLL
  • Stock Information
  • Founded
  • ABCL 2012
  • COLL 2002
  • Country
  • ABCL Canada
  • COLL United States
  • Employees
  • ABCL N/A
  • COLL N/A
  • Industry
  • ABCL Biotechnology: Pharmaceutical Preparations
  • COLL Biotechnology: Pharmaceutical Preparations
  • Sector
  • ABCL Health Care
  • COLL Health Care
  • Exchange
  • ABCL Nasdaq
  • COLL Nasdaq
  • Market Cap
  • ABCL 895.0M
  • COLL 1.1B
  • IPO Year
  • ABCL 2020
  • COLL 2015
  • Fundamental
  • Price
  • ABCL $2.68
  • COLL $30.78
  • Analyst Decision
  • ABCL Buy
  • COLL Strong Buy
  • Analyst Count
  • ABCL 3
  • COLL 6
  • Target Price
  • ABCL $8.50
  • COLL $42.00
  • AVG Volume (30 Days)
  • ABCL 2.4M
  • COLL 439.3K
  • Earning Date
  • ABCL 11-04-2024
  • COLL 11-07-2024
  • Dividend Yield
  • ABCL N/A
  • COLL N/A
  • EPS Growth
  • ABCL N/A
  • COLL 757.11
  • EPS
  • ABCL N/A
  • COLL 2.16
  • Revenue
  • ABCL $32,962,000.00
  • COLL $599,245,000.00
  • Revenue This Year
  • ABCL N/A
  • COLL $13.20
  • Revenue Next Year
  • ABCL $36.56
  • COLL $17.63
  • P/E Ratio
  • ABCL N/A
  • COLL $14.32
  • Revenue Growth
  • ABCL N/A
  • COLL 9.62
  • 52 Week Low
  • ABCL $2.34
  • COLL $28.97
  • 52 Week High
  • ABCL $6.06
  • COLL $42.29
  • Technical
  • Relative Strength Index (RSI)
  • ABCL 44.26
  • COLL 48.70
  • Support Level
  • ABCL $2.76
  • COLL $29.67
  • Resistance Level
  • ABCL $3.05
  • COLL $31.10
  • Average True Range (ATR)
  • ABCL 0.16
  • COLL 0.98
  • MACD
  • ABCL -0.03
  • COLL 0.26
  • Stochastic Oscillator
  • ABCL 0.00
  • COLL 69.41

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: